A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy

INTRODUCTION: Vaginal tenofovir (TFV) 1% gel may reduce incident HIV-1 and herpes simplex virus 2 infection. Pregnancy may increase risk of HIV acquisition, and incident HIV in pregnancy potentiates perinatal HIV transmission. Our objective was to investigate the safety and pharmacokinetics of seven...

Descripción completa

Detalles Bibliográficos
Autores principales: Beigi, Richard H, Noguchi, Lisa M, Montgomery, Elizabeth, Biggio, Joseph, Hendrix, Craig W, Marzinke, Mark A, Dai, James Y, Pan, Jason, Na Ayudhya, Ratiya Kunjara, Schwartz, Jill L, Isaacs, Karen, Piper, Jeanna M, Watts, D Heather
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034095/
https://www.ncbi.nlm.nih.gov/pubmed/27658440
http://dx.doi.org/10.7448/IAS.19.1.20990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034095/
https://www.ncbi.nlm.nih.gov/pubmed/27658440
http://dx.doi.org/10.7448/IAS.19.1.20990

Ejemplares similares